Protara Therapeutics, Inc. (TARA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Protara Therapeutics, Inc. (TARA) closed at USD 2.48 on 2026-10-14, a change of -51.3 % over the past year, with a market capitalization of USD 141.83M.

Protara Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Protara Therapeutics, Inc. key figures

Previous close

USD 2.48 (2026-10-14)

1-year change

-51.3 %

Market cap

USD 141.83M

Enterprise value

USD 2.08M

P/E ratio (trailing)

-1.92

P/E ratio (forward)

-1.42

EPS (trailing)

-1.25

EPS (forward)

-1.69

PEG ratio

n/a

Price to book

0.88

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.75

Employees

46

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Protara Therapeutics, Inc. and compare it with other stocks.